The role of histone deacetylase inhibitors in the treatment of metabolic dysfunction associated steatotic liver disease

Abstract

In recent years, increasing attention has been directed toward the role of epigenetic modifications in the management of metabolic dysfunction associated steatotic liver disease (MASLD). Given the critical involvement of epigenetic enzymes in regulating inflammatory processes that drive MASLD progression, pharmacological modulation of these pathways represents a promising avenue for the development of novel therapeutic strategies. Unlike conventional treatments, epigenetic-based therapies are designed to influence gene expression through the targeting of chromatinmodifying enzymes. Among these, histone deacetylase( HDAC) inhibitors have attracted particular interest in hepatology due to their antiproliferative effects and their capacity to trigger cell death through modulation of multiple HDAC-dependent substrates. Aim. Elucidating the role of HDAC inhibitors in the treatment of MASLD.